4548 logo

Seikagaku Corporation Stock Price

TSE:4548 Community·JP¥39.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

4548 Share Price Performance

JP¥717.00
106.00 (17.35%)
JP¥717.00
106.00 (17.35%)
Price JP¥717.00

4548 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet with acceptable track record.

3 Risks
1 Reward

Seikagaku Corporation Key Details

JP¥36.6b

Revenue

JP¥20.7b

Cost of Revenue

JP¥16.0b

Gross Profit

JP¥14.5b

Other Expenses

JP¥1.5b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 05, 2026
26.98
43.59%
4.02%
0.4%
View Full Analysis

About 4548

Founded
1947
Employees
1144
CEO
Kenji Mizutani
WebsiteView website
www.seikagaku.co.jp

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. It operates in two segments, Pharmaceuticals and LAL Business. The company offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation. It also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, the company develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals and medical devices manufacturing processes and water quality control of dialysate used in artificial dialysis. Further, its products under development include SI-6603 for lumbar disc herniation; SI-614, a dry eye treatment; SI-613 for osteoarthritis; SI-722 to treat interstitial cystitis and bladder pain syndrome; SI-613-ETP to treat enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was incorporated in 1947 and is headquartered in Tokyo, Japan.

Recent 4548 News & Updates

Analysis Article May 20

Seikagaku's (TSE:4548) Solid Earnings May Rest On Weak Foundations

The market for Seikagaku Corporation's ( TSE:4548 ) stock was strong after it released a healthy earnings report last...

Recent updates

No updates